A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of 2 dose levels of subcutaneious anakinra in patients with Still's disease

Administered By

Awarded By

Contributors

Start/End

  • October 26, 2017 - September 30, 2020